Dr. Voorhees on the Future Treatment Paradigm for Myeloma

Peter Voorhees, MD
Published: Tuesday, Aug 11, 2015



Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.

With an emergence of monoclonal antibodies, such as daratumumab and elotuzumab, it is likely that these agents will be administered in combination with existing therapies, Voorhees explains. Emerging checkpoint blockade agents are predicted to eradicate minimal residual disease in patients with myeloma.

Voorhees notes that it will be interesting to see if stem cell transplantation will remain a part of the treatment paradigm over the next decade. However, the procedure will likely remain beneficial to eligible patients.



Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.

With an emergence of monoclonal antibodies, such as daratumumab and elotuzumab, it is likely that these agents will be administered in combination with existing therapies, Voorhees explains. Emerging checkpoint blockade agents are predicted to eradicate minimal residual disease in patients with myeloma.

Voorhees notes that it will be interesting to see if stem cell transplantation will remain a part of the treatment paradigm over the next decade. However, the procedure will likely remain beneficial to eligible patients.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x